TAE Life Sciences (TLS) has signed a letter of intent with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to develop boron-based drug compounds for precision cancer therapy.
The compounds will form an important component for Boron Neutron Capture Therapy (BNCT).
Go deeper with GlobalData
This collaboration is claimed to be the “first-of-its-kind” where US-based academic-industry alliance is focused on advancing BNCT drug innovation and translational research.
By enhancing boron delivery agents, TLS and OSUCCC seek to fully realise the potential of BNCT as a potent, highly targeted, and relatively non-toxic treatment, establishing it as a novel approach in the next generation of precision oncology.
The partnership’s initial focus will be on preclinical evaluation of TLS’s boron-10 drugs in cellular and animal models, utilising Ohio State’s neutron source optimised for BNCT research.
Concurrently, the parties will work on co-developing boron drugs for BNCT and related applications to tap new possibilities in treating precision cancer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOhio State University Brain Tumor Program director and professor Dr Arnab Chakravarti said: “BNCT offers an unprecedented opportunity to treat malignancies that are otherwise unresponsive to conventional therapies, while sparing healthy tissue.
“Our laboratory is uniquely poised to lead this next wave of boron drug innovation, and we are excited to collaborate with TLS in accelerating this effort on a global scale.”
TLS CEO RobertHill said: “We are deeply honoured to collaborate with Dr Chakravarti and his world-class team of research and clinical experts.
He added that this collaboration is a fundamental step towards establishing accelerator-based BNCT and hastens the journey towards cancer therapies.
He further underscored the significance of international clinical evidence, especially from Taiwan, Europe, and Japan, which supports BNCT’s capability in achieving durable responses in cancer patients who are otherwise resistant to treatment.
